Successful prenatal mannose treatment for congenital disorder of glycosylation-Ia in mice.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22157680.
- Also identified by DOI 10.1038/nm.2548.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Congenital disorder of glycosylation-Ia (CDG-Ia, also known as PMM2-CDG) is caused by mutations in the gene that encodes phosphomannomutase 2 (PMM2, EC 5.4.2.8) leading to a multisystemic disease with severe psychomotor and mental retardation. In a hypomorphic Pmm2 mouse model, we were able to overcome embryonic lethality by feeding mannose to pregnant dams. The results underline the essential role of glycosylation in embryonic development and may open new treatment options for this disease.
Medical subject headings
- Congenital Disorders of Glycosylation
- Embryonic Development
- Mannose
- Phosphotransferases (Phosphomutases)
- Prenatal Care